

Correction: Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer

In this article (*Cancer Discovery* 2016;6:270–85), which was published in the March 2016 issue of *Cancer Discovery* (1), the conflict of interest disclosure statement is incomplete as it is written. The complete disclosure statement is provided below. The authors regret this error.

M.A. Tempero reports receiving commercial research support from Pharmacyclics. B.Y. Chang has ownership interest (including patents) in AbbVie and Pharmacyclics. J.A. Varner reports receiving a commercial research grant from Acerta LLC and is a consultant/advisory board member for the same. L.M. Coussens reports receiving a commercial research grant from Acerta Pharma and is a consultant/advisory board member for Pharmacyclics. No potential conflicts of interest were disclosed by the other authors.

REFERENCE

1. Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, et al. Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. *Cancer Discov* 2016;6:270–85.

Published OnlineFirst June 13, 2016.

doi: 10.1158/2159-8290.CD-16-0626

©2016 American Association for Cancer Research.